However, there was no survival advantage among GBM patients with Class I alterations compared to other patients with GBM, suggesting the transition to GBM allows cells to compensate for any growth disadvantage of BRAF-driven ERK dependence27. This evidence concerns the gene BRAF and glioblastoma.